Cormorant Asset Management LP 13D and 13G filings for Ambrx Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-03-13 4:00 pm Purchase |
2023-03-03 | 13G | Ambrx Biopharma Inc. AMAM |
Cormorant Asset Management LP | 52,500,000 17.730% |
36,145,298 (+221.01%) |
Filing |
| 2023-02-14 3:12 pm Sale |
2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
Cormorant Asset Management LP | 16,354,702 6.050% |
-911,442 (-5.28%) |
Filing |
| 2022-02-14 3:09 pm Sale |
2021-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
Cormorant Asset Management LP | 17,266,144 7.060% |
-138,558 (-0.80%) |
Filing |
| 2021-07-02 4:12 pm Purchase |
2021-06-22 | 13G | Ambrx Biopharma Inc. AMAM |
Cormorant Asset Management LP | 17,404,702 6.600% |
17,404,702 (New Position) |
Filing |